Abstract
Down syndrome (DS) is the most common genetically defined cause of intellectual disability and accounts for over 50% of the cases of Alzheimer-type dementia in persons younger than 50 years of age. At present, no pharmacotherapy aimed at counteracting either the neurodevelopmental or the neurodegenerative component of this genetic disorder has been approved. Recent preclinical and clinical work on the N-methyl-D-aspartate (NMDA) receptor antagonist memantine give us some reason for optimism, at least in relation to the potential for a partial pharmacological improvement of hippocampus dependent memory deficits associated with DS. Here, we will review briefly the roles of NMDA receptors in health and disease, including the glutamatergic hypothesis for Alzheimer disease. Then, we will describe the basis for a glutamatergic hypothesis for DS, by reviewing the available preclinical evidence and assessing potential molecular mechanisms for NMDA receptor dysfunction in DS. A short description of the first two clinical trials of memantine in young and older adults with DS will follow. We will conclude by reviewing three caregiver reports from our recent clinical study and some lessons we have learned designing and conducting the first translational study in the field of DS to arise directly from experimental results in animal models.
Keywords: Down syndrome, Alzheimer disease, Trisomy 21, Ts65Dn mouse, Memantine, N-methyl-D-aspartate receptor, Long-term potentiation, Long-term depression.
CNS & Neurological Disorders - Drug Targets
Title:The Glutamatergic Hypothesis for Down Syndrome: The Potential Use of N-Methyl-D-Aspartate Receptor Antagonists to Enhance Cognition and Decelerate Neurodegeneration
Volume: 13 Issue: 1
Author(s): Alberto C.S. Costa
Affiliation:
Keywords: Down syndrome, Alzheimer disease, Trisomy 21, Ts65Dn mouse, Memantine, N-methyl-D-aspartate receptor, Long-term potentiation, Long-term depression.
Abstract: Down syndrome (DS) is the most common genetically defined cause of intellectual disability and accounts for over 50% of the cases of Alzheimer-type dementia in persons younger than 50 years of age. At present, no pharmacotherapy aimed at counteracting either the neurodevelopmental or the neurodegenerative component of this genetic disorder has been approved. Recent preclinical and clinical work on the N-methyl-D-aspartate (NMDA) receptor antagonist memantine give us some reason for optimism, at least in relation to the potential for a partial pharmacological improvement of hippocampus dependent memory deficits associated with DS. Here, we will review briefly the roles of NMDA receptors in health and disease, including the glutamatergic hypothesis for Alzheimer disease. Then, we will describe the basis for a glutamatergic hypothesis for DS, by reviewing the available preclinical evidence and assessing potential molecular mechanisms for NMDA receptor dysfunction in DS. A short description of the first two clinical trials of memantine in young and older adults with DS will follow. We will conclude by reviewing three caregiver reports from our recent clinical study and some lessons we have learned designing and conducting the first translational study in the field of DS to arise directly from experimental results in animal models.
Export Options
About this article
Cite this article as:
Costa C.S. Alberto, The Glutamatergic Hypothesis for Down Syndrome: The Potential Use of N-Methyl-D-Aspartate Receptor Antagonists to Enhance Cognition and Decelerate Neurodegeneration, CNS & Neurological Disorders - Drug Targets 2014; 13 (1) . https://dx.doi.org/10.2174/18715273113126660183
DOI https://dx.doi.org/10.2174/18715273113126660183 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Review of Theoretical Studies for Prediction of Neurodegenerative Inhibitors
Mini-Reviews in Medicinal Chemistry Use of the Bradykinin Agonist, Cereport as a Pharmacological Means of Increasing Drug Delivery to the CNS
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Panomics Approach in Neurodegenerative Disorders
Current Medicinal Chemistry Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease
Current Medicinal Chemistry Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier
Current Neuropharmacology Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology Modulators of Voltage-Dependent Calcium Channels for the Treatment of Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Reduction of Aβ Levels in the Sprague Dawley Rat After Oral Administration of the Functional g-Secretase Inhibitor, DAPT: A Novel Non- Transgenic Model for Aβ Production Inhibitors
Current Pharmaceutical Design <i>Uncaria rhynchophylla</i> and its Major Constituents on Central Nervous System: A Review on Their Pharmacological Actions
Current Vascular Pharmacology Alzheimers Disease Burdens African-Americans: A Review of Epidemiological Risk Factors and Implications for Prevention and Treatment
Current Psychiatry Reviews Evidence of Redox Unbalance in Post-Acute Ischemic Stroke Patients
Current Neurovascular Research Was Phenserine a Failure or Were Investigators Mislead by Methods?
Current Alzheimer Research The Many Roles of Chemokine Receptors in Neurodegenerative Disorders: Emerging New Therapeutical Strategies
Current Medicinal Chemistry Non-Demented Individuals with Alzheimer’s Disease Neuropathology: Resistance to Cognitive Decline May Reveal New Treatment Strategies
Current Pharmaceutical Design Restless Legs Syndrome/Willis-Ekbom Disease and Periodic Limb Movements: A Comprehensive Review of Epidemiology, Pathophysiology, Diagnosis and Treatment Considerations
Current Rheumatology Reviews Alzheimer’s and Type 2 Diabetes Treatment via Common Enzyme Targeting
CNS & Neurological Disorders - Drug Targets Recent Advances in Prion Chemotherapeutics
Infectious Disorders - Drug Targets Emerging Vascular Risk Factors in Women: Any Differences from Men?
Current Medicinal Chemistry Electroporation: An Avenue for Transdermal Drug Delivery
Current Drug Delivery The Relationship Between Hypertensive Retinopathy and Angiotensin Converting Enzyme Gene Polymorphism
Cardiovascular & Hematological Disorders-Drug Targets